144 related articles for article (PubMed ID: 6298424)
1. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
Walker KA; Boots MR; Stubbins JF; Rogers ME; Davis CW
J Med Chem; 1983 Feb; 26(2):174-81. PubMed ID: 6298424
[TBL] [Abstract][Full Text] [Related]
2. 1-(4-Aminophenyl)isoquinoline derivatives. Potent inhibitors of calcium-independent and calcium-dependent phosphodiesterases from rat cerebral cortex.
Davis CW; Walker KA
Biochem Pharmacol; 1984 Apr; 33(8):1205-12. PubMed ID: 6324818
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
5. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
6. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
Ahluwalia GS; Rhoads AR
Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
[TBL] [Abstract][Full Text] [Related]
7. Studies on griseolic acid derivatives. I. Synthesis of substituted derivatives of griseolic acid at the N1, C6, C2' or C7' position and their biological activities.
Kaneko M; Murofushi Y; Kimura M; Yamazaki M; Iijima Y
Nucleic Acids Symp Ser; 1985; (16):89-92. PubMed ID: 3003711
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
Butt NM; Saeed SA; Collier HO
Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
[No Abstract] [Full Text] [Related]
9. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some pentasubstituted quercetin analogs.
Picq M; Prigent AF; Nemoz G; Pacheco H
Biochem Pharmacol; 1982 Sep; 31(17):2777-82. PubMed ID: 6291544
[TBL] [Abstract][Full Text] [Related]
10. Selective alteration of Ca2+-dependent and Ca2+-independent cyclic nucleotide phosphodiesterase activity in rat cerebral cortex by cyclic nucleotides and their analogs.
Davis CW
Biochim Biophys Acta; 1982 Jul; 705(1):1-7. PubMed ID: 6288105
[TBL] [Abstract][Full Text] [Related]
11. RMI 12330A, an inhibitor of cyclic nucleotide phosphodiesterases and adenylate cyclase in kidney preparations.
Hunt NH; Evans T
Biochim Biophys Acta; 1980 Jun; 613(2):499-506. PubMed ID: 6256001
[TBL] [Abstract][Full Text] [Related]
12. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
13. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
Rusin LJ; Duell EA; Voorhees JJ
J Invest Dermatol; 1978 Aug; 71(2):154-6. PubMed ID: 210235
[TBL] [Abstract][Full Text] [Related]
14. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.
Frossard N; Landry Y; Pauli G; Ruckstuhl M
Br J Pharmacol; 1981 Aug; 73(4):933-8. PubMed ID: 6168323
[TBL] [Abstract][Full Text] [Related]
15. Inhibition cyclic nucleotide phosphodiesterase by FPL 55712, an SRS-A antagonist.
Chasin M; Scott C
Biochem Pharmacol; 1978; 27(16):2065-7. PubMed ID: 214090
[No Abstract] [Full Text] [Related]
16. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
Némoz G; Prigent AF; Picq M; Pacheco H
Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
[No Abstract] [Full Text] [Related]
17. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
18. Effects of divalent metals on the specificity of inhibitors of the cyclic nucleotide phosphodiesterases from bovine heart.
Donnelly TE; Barron B
Biochim Biophys Acta; 1981 Jan; 657(1):168-78. PubMed ID: 6260197
[TBL] [Abstract][Full Text] [Related]
19. Different sensitivites of cyclic nucleotide phosphodiesterases of rat brain and lung to inhibition by new anti-allergic chromones [proceedings].
Saeed SA; Butt NM; Spicer JW; Warren BT
Biochem Soc Trans; 1979 Dec; 7(6):1308-10. PubMed ID: 231533
[No Abstract] [Full Text] [Related]
20. Methylxanthine inhibitors of phosphodiesterases.
Wells JN; Miller JR
Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
[No Abstract] [Full Text] [Related]
[Next] [New Search]
